Compare iShares MSCI India ETF (INDA) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI India ETF vs Sanofi SA — how do they compare? iShares MSCI India ETF trades at $46.03 (market cap $5.73B), while Sanofi SA trades at $40.04 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 16.6× iShares MSCI India ETF's market cap, and Sanofi SA pays a 6.01% dividend while iShares MSCI India ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI India ETF for 58 Days and Sanofi SA for 94 Days on average.
| INDA | SNY | |
|---|---|---|
Market Cap | $5.73B | $95.18B |
Volume | 6,797,522 | 2,995,646 |
Sector | Broad Market / Factor | Health |
52-Week High | $55.29 | $52.34 |
52-Week Low | $45.42 | $39.51 |
Typical Hold Time | 58 Days | 94 Days |
Enterprise Value | — | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDA trades at $45.98, down 0.3% with bearish technical signals showing 19 sell indicators versus 5 buy signals. The ETF faces headwinds from India's economic challenges including coal power shortages, monsoon concerns, and pharma sector export issues. Technical indicators show oversold conditions with RSI readings below 16, suggesting potential for near-term bounce despite the dominant bearish trend.
The outlook remains cautious as India's market composition with heavy banking sector exposure and external pressures from US tariff tensions create uncertainty. Key support at $45 provides critical technical level, while sector-specific challenges in technology and pharmaceuticals warrant careful monitoring of India's economic resilience.
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
